Increased dopamine transmission in schizophrenia: relationship to illness phases.
about
The dopamine hypothesis of schizophrenia: version III--the final common pathwayLimbic and cortical information processing in the nucleus accumbensProbing GABA receptor function in schizophrenia with iomazenilSocial predictors of psychotic experiences: specificity and psychological mechanismsIncreased baseline occupancy of D2 receptors by dopamine in schizophreniaAlterations of Dopamine D2 Receptors and Related Receptor-Interacting Proteins in Schizophrenia: The Pivotal Position of Dopamine Supersensitivity Psychosis in Treatment-Resistant SchizophreniaThe development, past achievements, and future directions of brain PETEmotional and cognitive dysregulation in schizophrenia and depression: understanding common and distinct behavioral and neural mechanismsMaking Sense of: Sensitization in SchizophreniaCannabidiol, among Other Cannabinoid Drugs, Modulates Prepulse Inhibition of Startle in the SHR Animal Model: Implications for Schizophrenia PharmacotherapyA network of dopaminergic gene variations implicated as risk factors for schizophreniaThe neurodevelopmental impact of prenatal infections at different times of pregnancy: the earlier the worse?Prenatal inflammation-induced hypoferremia alters dopamine function in the adult offspring in rat: relevance for schizophrenia.Amphetamine sensitization alters reward processing in the human striatum and amygdala.Amphetamine-induced Fos is reduced in limbic cortical regions but not in the caudate or accumbens in a genetic model of NMDA receptor hypofunctionDysconnection in schizophrenia: from abnormal synaptic plasticity to failures of self-monitoringPotential of GABA-ergic cell therapy for schizophrenia, neuropathic pain, and Alzheimer's and Parkinson's diseases.Negative visuospatial priming in isolation-reared rats: Evidence of resistance to the disruptive effects of amphetamine.Genetic Disruption of Arc/Arg3.1 in Mice Causes Alterations in Dopamine and Neurobehavioral Phenotypes Related to Schizophrenia.Adolescent olanzapine sensitization is correlated with hippocampal stem cell proliferation in a maternal immune activation rat model of schizophreniaDisruption of mGluR5 in parvalbumin-positive interneurons induces core features of neurodevelopmental disorders.Neurophysiological and neurochemical animal models of schizophrenia: focus on glutamateAltered serine/threonine kinase activity in schizophreniaDopaminergic contributions to hippocampal pathophysiology in schizophrenia: a computational studyPostmortem brain: an underutilized substrate for studying severe mental illnessOptimal treatment of Alzheimer's disease psychosis: challenges and solutions.Genetics, cognition, and neurobiology of schizotypal personality: a review of the overlap with schizophrenia.Enhanced effects of amphetamine but reduced effects of the hallucinogen, 5-MeO-DMT, on locomotor activity in 5-HT(1A) receptor knockout mice: implications for schizophrenia.Increased expression of receptor phosphotyrosine phosphatase-β/ζ is associated with molecular, cellular, behavioral and cognitive schizophrenia phenotypes.Prenatal stress: role in psychotic and depressive diseases.Goal representations and motivational drive in schizophrenia: the role of prefrontal-striatal interactions.Contrasting effects of increased and decreased dopamine transmission on latent inhibition in ovariectomized rats and their modulation by 17beta-estradiol: an animal model of menopausal psychosis?Evaluating early preventive antipsychotic and antidepressant drug treatment in an infection-based neurodevelopmental mouse model of schizophrenia.Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspectsA translational research approach to poor treatment response in patients with schizophrenia: clozapine-antipsychotic polypharmacyPharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission.Modulators in concert for cognition: modulator interactions in the prefrontal cortexA schizophrenia-related sensorimotor deficit links alpha 3-containing GABAA receptors to a dopamine hyperfunctionNeuroimaging studies in schizophrenia: an overview of research from Asia.Abnormalities of myelination in schizophrenia detected in vivo with MRI, and post-mortem with analysis of oligodendrocyte proteins.
P2860
Q22242827-E9584B15-A1ED-477E-BCD9-1E0512F9908CQ24594059-4D75AD4C-B5D6-4E7B-9B47-9EB8BB606449Q24601700-8C9C5630-23FF-4511-A392-8C0352EE224FQ24643628-4786F5B8-AF9C-45DB-8E13-0449067C606AQ24676113-247C9132-40B1-4E21-B406-565F39542DEDQ26773403-E170D8F2-F4F5-44FD-963E-43F5A1277E0FQ27026331-4B4B97A2-0D3A-4512-90A1-9B9737AFDAD7Q28073684-6250FC91-BC86-4CA4-83C2-661087EA30F0Q28077939-CC646381-A4EC-41F6-AC17-305B4E9C1B6BQ28078534-977D69AA-9A8F-4BDC-8D0E-C0C8E7F74460Q28259093-0FE23356-3BCC-401C-ADE7-B97D8401C909Q28303485-4437A2E9-C6B3-4DA3-AF5E-74C18D1DE6F0Q28474235-18ECD448-2EE8-4938-87AE-CC494E3362E2Q28537648-AD2EF2E8-D4CF-48A4-8D55-A9FC976D4BB2Q28590145-FFFA09AF-DE3E-4F2B-98C1-BD78DD880295Q28754716-586CF7EA-252A-4C9A-91D7-F56AB28E1245Q30357529-CF1EB505-7DFD-4BD0-B70E-4B3E813C090BQ30368568-2BD4C5C4-7440-44DB-9B72-989C33A47345Q30375583-ED37956E-6F5C-4032-81DD-A3F8909505F0Q30375799-7E82086D-2EBB-4342-B6A0-158BF559F7F9Q30402048-95F5A6D9-B3D7-4A25-ABE9-F42CF347B7E3Q30403302-7A461FEA-F1CB-4277-B624-7C008721F196Q30409979-F3613C3D-94D4-41BB-A628-9F3502617B6DQ30410514-383229A6-57E2-4135-8B6F-675FE7A5A28EQ30422050-09AF5A74-DD2C-4A36-BAD0-30AAEEC6B80BQ30423717-49B17663-C2E6-488D-83AA-E57C02C9F7C9Q30442031-EE9E1A4E-6CEE-4015-953C-FB91697BB53EQ30445688-69018DA2-6D74-4ED5-A2E5-9148B95956D2Q30468818-6452B7D9-C7E6-40D6-B74E-F680A7913FAAQ30470115-6AAA05ED-523E-4B49-8B1F-6957F688D09DQ30474409-D3957D81-FF69-46C1-9855-B2134E739180Q30475350-BA450958-57D0-475D-8966-EC3A26551019Q30475712-6818433E-FC76-43D9-8A1D-42399B6B886EQ30476813-9843F9FC-BF37-4F3A-A9FF-5EF60B2B92F6Q30485065-4DE32D60-CA26-434A-A603-CEE174955D97Q30493133-02D1E35F-1FDA-4BA9-80EE-8B0067FAF8DDQ30493218-9CE96242-64C7-42F0-973F-2B09A58F24D9Q30500072-020A3265-67A4-4097-92C5-7A0C129F66BAQ30573043-21C42C82-4C1A-477A-8FC6-BF73E6AE91F2Q30819593-C3A082B0-80C6-47B4-8859-8423E047C835
P2860
Increased dopamine transmission in schizophrenia: relationship to illness phases.
description
1999 nî lūn-bûn
@nan
1999 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Increased dopamine transmission in schizophrenia: relationship to illness phases.
@ast
Increased dopamine transmission in schizophrenia: relationship to illness phases.
@en
type
label
Increased dopamine transmission in schizophrenia: relationship to illness phases.
@ast
Increased dopamine transmission in schizophrenia: relationship to illness phases.
@en
prefLabel
Increased dopamine transmission in schizophrenia: relationship to illness phases.
@ast
Increased dopamine transmission in schizophrenia: relationship to illness phases.
@en
P2093
P1476
Increased dopamine transmission in schizophrenia: relationship to illness phases.
@en
P2093
P356
10.1016/S0006-3223(99)00067-0
P407
P577
1999-07-01T00:00:00Z